未登录Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers
Pistrosch, Frank; Matschke, Jan B.; Schipp, Dorothea; Schipp, Bernhard; Henkel, Elena; Weigmann, Ingo; Sradnick, Jan; Bornstein, Stefan R.; Birkenfeld, Andreas L.; Hanefeld, Markolf .png)
分享.png)
收藏分享 收藏 分享 收藏 The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and RationaleTschiderer, Lena; Seekircher, Lisa; Klingenschmid, Gerhard; Izzo, Raffaele; Baldassarre, Damiano; Iglseder, Bernhard; Calabresi, Laura; Liu, Jing; Price, JackieF.; Bae, Jang-Ho; Brouwers, FrankP.; de Groot, Eric; Schmidt, Caroline; Bergstroem, Goeran; Asci, Guelay; Gresele, Paolo; Okazaki, Shuhei; Kapellas, Kostas; Landecho, ManuelF.; Sattar, Naveed; Agewall, Stefan; Zou, Zhi-Yong; Byrne, Christopher D.; Nanayakkara, Prabath W. B.; Papagianni, Aikaterini; Witham, Miles D.; Bernal, Enrique; Ekart, Robert; van Agtmael, Michiel A.; Neves, Mario F.; Sato, Eiichi; Ezhov, Marat; Walters, Matthew; Olsen, Michael H.; Stolic, Radojica; Zozulinska-Ziolkiewicz, DorotaA.; Hanefeld, Markolf; Staub, Daniel; Nagai, Michiaki; Nieuwkerk, Pythia T.; Huisman, Menno V.; Kato, Akihiko; Honda, Hirokazu; Parraga, Grace; Magliano, Dianna; Gabriel, Rafael; Rundek, Tatjana; Espeland, Mark A.; Kiechl, Stefan; Willeit, Johann; Lind, Lars; Empana, Jean Philippe; Lonn, Eva; Tuomainen, Tomi-Pekka; Catapano, Alberico; Chien, Kuo-Liong; Sander, Dirk; Kavousi, Maryam; Beulens, Joline W. J.; Bots, Michiel L.; Sweeting, Michael J.; Lorenz, Matthias W.; Willeit, Peter 分享 收藏 Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial杜拉鲁肽与2型糖尿病的心血管结局 (REWIND): 一项双盲，随机安慰剂对照试验Gerstein, Hertzel C.; Colhoun, Helen M.; Dagenais, Gilles R.; Diaz, Rafael; Lakshmanan, Mark; Pais, Prem; Probstfield, Jeffrey; Riesmeyer, Jeffrey S.; Riddle, Matthew C.; Ryden, Lars; Xavier, Denis; Atisso, Charles Messan; Dyal, Leanne; Hall, Stephanie; Rao-Melacini, Purnima; Wong, Gloria; Avezum, Alvaro; Basile, Jan; Chung, Namsik; Conget, Ignacio; Cushman, William C.; Franek, Edward; Hancu, Nicolae; Hanefeld, Markolf; Holt, Shaun; Jansky, Petr; Keltai, Matyas; Lanas, Fernando; Leiter, Lawrence A.; Lopez-Jaramillo, Patricio; Cardona Munoz, Ernesto German; Pirags, Valdis; Pogosova, Nana; Raubenheimer, Peter J.; Shaw, Jonathan E.; Sheu, Wayne H-H; Temelkova-Kurktschiev, Theodora 分享 收藏 Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialGerstein, Hertzel C.; Colhoun, Helen M.; Dagenais, Gilles R.; Diaz, Rafael; Lakshmanan, Mark; Pais, Prem; Probstfield, Jeffrey; Botros, Fady T.; Riddle, Matthew C.; Ryden, Lars; Xavier, Denis; Atisso, Charles Messan; Dyal, Leanne; Hall, Stephanie; Rao-Melacini, Purnima; Wong, Gloria; Avezum, Alvaro; Basile, Jan; Chung, Namsik; Conget, Ignacio; Cushman, William C.; Franek, Edward; Hancu, Nicolae; Hanefeld, Markolf; Holt, Shaun; Jansky, Petr; Keltai, Matyas; Lanas, Fernando; Leiter, Lawrence A.; Lopez-Jaramillo, Patricio; Cardona Munoz, Ernesto German; Pirags, Valdis; Pogosova, Nana; Raubenheimer, J.; Shaw, Jonathan E.; Sheu, Wayne H-H; Temelkova-Kurktschiev, Theodora 分享 收藏 Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutideGerstein, Hertzel C.; Colhoun, Helen M.; Dagenais, Gilles R.; Diaz, Rafael; Lakshmanan, Mark; Pais, Prem; Probstfield, Jeffrey; Riddle, Matthew C.; Ryden, Lars; Xavier, Denis; Atisso, Charles M.; Avezum, Alvaro; Basile, Jan; Chung, Namsik; Conget, Ignacio; Cushman, William C.; Franek, Edward; Hancu, Nicolae; Hanefeld, Markolf; Holt, Shaun; Jansky, Petr; Keltai, Matyas; Lanas, Fernando; Leiter, Lawrence A.; Lopez-Jaramillo, Patricio; Cardona-Munoz, Ernesto G.; Pirags, Valdis; Pogosova, Nana; Raubenheimer, Peter J.; Shaw, Jonathan; Sheu, Wayne H-H.; Temelkova-Kurktschiev, Theodora 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized TrialRosenstock, Julio; Aronson, Ronnie; Grunberger, George; Hanefeld, Markolf; Piatti, PierMarco; Serusclat, Pierre; Cheng, Xi; Zhou, Tianyue; Niemoeller, Elisabeth; Souhami, Elisabeth; Davies, Melanie 分享 收藏 分享 收藏 Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 TrialRosenstock, Julio; Guerci, Bruno; Hanefeld, Markolf; Gentile, Sandro; Aronson, Ronnie; Tinahones, Francisco J.; Roy-Duval, Christine; Souhami, Elisabeth; Wardecki, Marek; Ye, Jenny; Perfetti, Riccardo; Heller, Simon 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
